An Exploratory Clinical Study of Adebelimumab in Combination With Famitinib and Chemotherapy in Patients With NSCLC
Conditions: NSCLC Interventions: Drug: Adebelimumab+Famitinib + FOLFIRI+Ariely Sponsors: Jiangsu Province Nanjing Brain Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 27, 2024 Category: Research Source Type: clinical trials
A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Advanced NSCLC With Leptomeningeal Metastasis
Conditions: NSCLC Interventions: Drug: combination of Trilaciclib and Pemetrexed Sponsors: Jiangsu Province Nanjing Brain Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 27, 2024 Category: Research Source Type: clinical trials
HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma
Conditions: Hepatocellular Carcinoma; Lenvatinib; PD-1 Inhibitor; Hepatic Arterial Infusion Chemotherapy Interventions: Procedure: Hepatic arterial infusion chemotherapy; Drug: Lenvatinib; Drug: Tislelizumab; Drug: Toripalimab; Drug: Sintilimab; Drug: Camrelizumab Sponsors: Sun Yat-sen University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 27, 2024 Category: Research Source Type: clinical trials
Pulsed Electromagnetic Fields (PEMFs) - A Highly Selective Breast CAncer Treatment pLatform (PASCAL)
Conditions: Breast Cancer Interventions: Device: Pulsed electromagnetic fields (PEMFs); Drug: Anthracycline-based chemotherapy Sponsors: National University Hospital, Singapore; National University of Singapore Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 27, 2024 Category: Research Source Type: clinical trials
Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI
Conditions: Pancreatic Adenocarcinoma; Ampulla of Vater Carcinoma; Adrenocortical Carcinoma; Neuroendocrine Carcinoma; Soft Tissue Sarcoma; Small Bowel Adenocarcinoma; Duodenum Adenocarcinoma; Gastric Adenocarcinoma Interventions: Drug: Dostarlimab; Drug: Chemotherapy Sponsors: UNICANCER; National Cancer Institute, France; GlaxoSmithKline Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 27, 2024 Category: Research Source Type: clinical trials
PrefeRences And ChemoTherapy In Breast Cancer patiEnts
Conditions: Female Breast Cancer Interventions: Other: Completion of questionnaires Sponsors: European Institute of Oncology Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 27, 2024 Category: Research Source Type: clinical trials
Stop and go Strategy as First-line Treatment for Widely Metastatic Nasopharyngeal Carcinoma
Conditions: Metastatic Nasopharyngeal Carcinoma; Intermittent Systematic Chemotherapy Interventions: Drug: Gemcitabine; Drug: Cisplatin; Drug: Paclitaxel protein-bound; Drug: Capecitabine; Drug: Tislelizumab Sponsors: Fujian Cancer Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 26, 2024 Category: Research Source Type: clinical trials
Parenchymal Sparing Hepatectomy in Post-chemotherapy Liver Atrophy
Conditions: Colorectal Cancer Stage IV Interventions: Procedure: Hepatectomy Sponsors: Azienda Ospedaliero Universitaria Maggiore della Carita Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 26, 2024 Category: Research Source Type: clinical trials
A Single-arm Pilot Study of First-line Treatment With Carbognilumab Combined With Chemotherapy in Patients With STK11-mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer
Conditions: Non-small Cell Lung Cancer Interventions: Drug: cadonilimab Sponsors: Guangzhou Institute of Respiratory Disease Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 26, 2024 Category: Research Source Type: clinical trials
Digestive Tract Cancer and CIPN
Conditions: Digestive Tract Cancer; Chemotherapy-induced Peripheral Neuropathy; Remote Exercise Interventions: Other: remote home-based exercise therapy group; Other: supervised exercise therapy group; Other: regular care group Sponsors: National Cheng-Kung University Hospital; National Cheng Kung University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 26, 2024 Category: Research Source Type: clinical trials
NEPA Combined With Olanzapine, Dexamethasone-sparing for the Effect of CINV in Patients Receiving HEC Regimens
Conditions: Chemotherapy-induced Nausea and Vomiting; Highly Emetogenic Chemotherapy Interventions: Drug: Netupitant / Palonosetron Oral Capsule [Akynzeo]; Drug: Olanzapine; Drug: Dexamethasone Oral Sponsors: Fudan University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 26, 2024 Category: Research Source Type: clinical trials
HIVEC in Patients With Non-Muscle-Invasive Bladder Cancer
Conditions: Non-Muscle-Invasive Bladder Cancer Interventions: Procedure: TURBT; Procedure: HIVEC; Procedure: Intravesical Chemotherapy; Drug: Gemcitabine Sponsors: Affiliated Cancer Hospital& Institute of Guangzhou Medical University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 25, 2024 Category: Research Source Type: clinical trials
ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer
Conditions: HER2-positive Breast Cancer; HER2-positive Gastric Cancer; HER2 Positive Solid Tumors; HER2 Amplification; Colorectal Cancer Interventions: Drug: ELVN-002; Drug: Trastuzumab; Drug: 5-Fluorouracil; Drug: Oxaliplatin; Drug: Capecitabine; Drug: Eribulin; Drug: paclitaxel; Drug: Leucovorin Sponsors: Enliven Therapeutics Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 25, 2024 Category: Research Source Type: clinical trials
A Study of Trilaciclib Combined With Chemotherapy in the Treatment of NSCLC
Conditions: NSCLC Interventions: Drug: Trilaciclib Injection Sponsors: Taixing People ' s Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 25, 2024 Category: Research Source Type: clinical trials
Differences in Rate of Decline in CT-defined Skeletal Muscle Mass and Physical Performance in Patients With Advanced Non-small Cell Lung Cancer Receiving Chemotherapy and Targeted Therapy/Immunotherapy, Before and After Treatment.
Conditions: Advanced Lung Cancer; Sarcopenia Interventions: Drug: Chemotherapy drug; Drug: Targeted Agent; Drug: Immunotherapy Sponsors: Prince of Songkla University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 22, 2024 Category: Research Source Type: clinical trials
